688185 Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$51.08 |
| 52 Week High | HK$101.87 |
| 52 Week Low | HK$44.02 |
| Beta | 0.58 |
| 1 Month Change | -0.53% |
| 3 Month Change | 2.34% |
| 1 Year Change | -48.14% |
| 3 Year Change | -88.58% |
| 5 Year Change | n/a |
| Change since IPO | -87.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688185 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 6.4% | 5.0% | 3.1% |
| 1Y | -48.1% | -22.0% | -13.1% |
Return vs Industry: 688185 underperformed the CN Biotechs industry which returned -22% over the past year.
Return vs Market: 688185 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 688185 volatility | |
|---|---|
| 688185 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688185 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688185's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,494 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| 688185 fundamental statistics | |
|---|---|
| Market cap | CN¥8.05b |
| Earnings (TTM) | -CN¥1.51b |
| Revenue (TTM) | CN¥370.81m |
11.1x
P/S Ratio-2.7x
P/E RatioIs 688185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688185 income statement (TTM) | |
|---|---|
| Revenue | CN¥370.81m |
| Cost of Revenue | CN¥781.88m |
| Gross Profit | -CN¥411.06m |
| Other Expenses | CN¥1.10b |
| Earnings | -CN¥1.51b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.13 |
| Gross Margin | -110.85% |
| Net Profit Margin | -408.10% |
| Debt/Equity Ratio | 41.2% |
How did 688185 perform over the long term?
See historical performance and comparison